Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 112, Issue 6, 2005, Pages 692-695

  Beral, Valerie ^a   Reeves, Gillian ^a   Banks, Emily ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN;

BODY MASS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL RESEARCH; COLORECTAL CANCER; DRUG EFFECT; FEMALE; FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HIP FRACTURES; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 20744454307     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2005.00541.x     Document Type: Review

References (26)

1. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360:942-944.
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
3. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-967.
4. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-1249.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
6. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofield PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002;109:1056-1062.
7. The ESPRIT team. Oestrogen therapy for prevention of re-infarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;359:2001-2008.
8. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440.
9. Holmberg L, Anderson H, for the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-455.
10. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with a hysterectomy. The Women's Health Initiative Randomised Controlled Trial. JAMA 2004;291:1701-1712.
11. The Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials 1998;19:61-109.
12. Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise - was it inevitable? Climacteric 2002;5:317-325.
13. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-153.
14. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004;363:1728-1731.
15. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. Br J Obstet Gynaecol 2002;109:1319-1330.
16. Beral V, Banks E, Reeves G, et al. The effect of hormone replacement therapy on breast and other cancers. In: Menopause and Hormone Replacement. RCOG Press, 2004:136-150.
17. Banks E, Beral V, Reeves G, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 2004;291:2212-2220.
18. Grady D, Gebretsadjk T, Kerlikowski K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynaecol 1995;85:304-313.
19. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350:1047-1059.
20. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362: 419-427.
21. Manson JA, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
22. Committee on Safety of Medicines. Review of the evidence on the long-term safety of HRT. Curr Probl Pharmacovigilance 2004;30:4-7.
23. The European Agency for the Evaluation of Medicinal Products. EMEA public statement on recent publications regarding hormone replacement therapy. 3 December 2003. Available: http://www.emea.eu. int/index/indexhl.htm.
24. U.S. Food and Drug Administration. The estrogen and progestin dilemma: new advice, labeling guidelines. Available: http://www.fda. gov/fdac/features/ 2003/203_estrogen.html.
25. Consensus Views. In: Menopause and Hormone Replacement. London: RCOG Press, 2004:345-350
26. Lumsden MA. The HRT maze: is there a way through? Br J Obstet Gynaecol. In press.